Precancerous Lesions of the Cervix: Better Care Options
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at better ways to manage early precancerous changes in the cervix (called high-grade lesions) without surgery. It aims to find which approaches work best for women who have not been vaccinated against HPV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 46 years old.
- You have had a cervical biopsy that found a high-grade precancerous lesion (CIN 2 or 3).
- You have never received the HPV vaccine.
- You do not have a weak immune system or an active autoimmune disease.
- You have not had previous cryotherapy (freezing) treatment for a cervical lesion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at doing a diagnostic cervical conization (a cone-shaped tissue biopsy) when HPV remains persistent and there are warning signs, but initial pathology does not show precancer. It aims to find hidden precancer earlier or better understand HPV-related changes that were missed.
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
This study tests ways to improve cervical cancer screening for women ages 30–65. It may help catch cervical cancer early or prevent it entirely by finding precancerous changes.
This study looks at whether selenium levels in your body are linked to HPV and cervical changes. It may help us understand how to better prevent or treat cervical issues.
This study watches to see if early precancerous cells (CIN 2 or 3) on the cervix can go away without treatment, especially in women under 40. It helps doctors understand who might avoid surgery.
This study follows women with an early abnormal cervix cell change (CIN2/CIN2-3) to see how HPV DNA “integration” relates to whether the condition improves or worsens. It may help doctors better predict prognosis and guide safer monitoring, especially if you want to become pregnant.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.